Page 1553
www.rsisinternational.org
INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,
MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)
ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue V, May 2026
Indian Neurotherapy in Obsessive–Compulsive Disorder (OCD)
Management - A Case Report
Manvi Tara Aswani¹, Inderjeet Singh², Ranjan³
¹ M. Voc 2nd Year Student, Lajpat Rai Mehra Neurotherapy Research & Training Institute
(LMNTRTI), Bikaner, Rajasthan, India
² Neurotherapist; Bachelor of Arts; Master of Arts (Yoga); Pharmacy (Ayurveda), LMNTRTI, Punjab,
India
³ Neurotherapist and Yoga Therapist; Bachelor of Arts, LMNTRTI, Punjab, India
DOI:
https://doi.org/10.51583/IJLTEMAS.2026.150500123
Received: 15 May 2026; Accepted: 20 May 2026; Published: 08 June 2026
ABSTRACT
Background: Obsessive–Compulsive Disorder (OCD) affects 2.3% of the global population and is characterised
by persistent intrusive thoughts and compulsive behaviours causing severe functional impairment. Despite
pharmacological and psychotherapeutic advances, a substantial proportion of patients experience incomplete
response, relapse, or limited access to evidence-based care. Indian Neurotherapy, a non-invasive naturopathic
system employing targeted neuromuscular stimulation, offers a potentially viable complementary approach, yet
remains undocumented in peer-reviewed clinical literature. Objective: To evaluate clinical outcomes of
structured Indian Neurotherapy in a severe, treatment-refractory OCD case using the OCI-R as primary outcome
measure, with 10-month follow-up. Methods: CARE-compliant observational single-case study at LMNTRTI,
Punjab, India. Participant: 43-year-old female with 25-year OCD history, multiple comorbidities, and prior
treatment failure across allopathic, Ayurvedic, and homoeopathic systems. OCI-R administered at baseline (14
June 2025), after 6 sessions (20 June 2025), post-intervention (22 August 2025), and followed up to 11 March
2026 (9 months). Results: OCI-R scores: 69/72 (severe) → 35/72 (49.3% reduction after 6 sessions) → 0/72
(complete remission at 10 weeks). At 9-month follow-up, the participant returned for general wellness goals
with no OCD symptom recurrence. Conclusion: This CARE-compliant case report demonstrates complete,
sustained remission of severe, long-standing OCD through Indian Neurotherapy, with mechanistic plausibility
grounded in autonomic, vagal, serotonergic, and neurochemical regulatory pathways. Controlled trials are
urgently warranted.
Keywords: Obsessive–Compulsive Disorder; Indian Neurotherapy; OCI-R; Integrative Mental Health;
Autonomic Nervous System; Vagal Tone Modulation; LMNTRTI; Case Report; Complementary Medicine
INTRODUCTION
Obsessive–Compulsive Disorder (OCD) is a chronic and disabling mental health condition characterised by ego-
dystonic obsessive thoughts, images, or urges generating significant anxiety, paired with time-consuming
compulsive behaviours aimed at neutralising distress (APA, 2022). The World Health Organization has
consistently ranked OCD among the top ten most debilitating illnesses globally due to the profound functional
impairment it inflicts across occupational, social, and interpersonal domains (WHO, 2022). Epidemiological
data indicate a lifetime prevalence of approximately 2.3%, with onset typically occurring in adolescence or early
adulthood and a characteristically chronic, waxing-and-waning course (Ruscio et al., 2010). Among individuals
with OCD, comorbid psychiatric and medical conditions are the rule rather than the exception, significantly
compounding treatment complexity and prognosis (Sharma et al., 2021).
The neurobiological underpinnings of OCD are well characterised and primarily involve dysregulation of
cortico-striato-thalamo-cortical (CSTC) circuits, serotonergic and glutamatergic neurotransmission, and aberrant
Page 1554
www.rsisinternational.org
INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,
MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)
ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue V, May 2026
fear-conditioning and habit-learning pathways (Stein et al., 2019; Goodman et al., 2021). First-line treatment
with serotonin reuptake inhibitors (SSRIs) yields clinically meaningful response—defined as ≥25–35%
symptom reduction—in approximately 40–60% of patients, while combined pharmacotherapy and cognitive
behavioural therapy with exposure and response prevention (ERP) achieves superior but still incomplete
outcomes in 60–70% (Skapinakis et al., 2016; Hirschtritt et al., 2017). Complete remission with pharmacological
treatment alone remains rare, achieved in only 20–25% of patients (Skoog & Skoog, 1999). Furthermore, relapse
upon medication discontinuation, intolerance of side effects, and limited accessibility—particularly in rural and
resource-constrained Indian settings—represent ongoing barriers to effective care (Abramowitz et al., 2009).
These therapeutic gaps have stimulated growing interest in complementary and integrative approaches (Sarris et
al., 2012). Indian systems of medicine—including Yoga, Ayurveda, and acupressure—are increasingly
investigated for their neurophysiological plausibility and mental health utility (Mukherjee et al., 2017). Indian
Neurotherapy, described in Box 1, is a non-invasive naturopathic system employing external manual pressure-
based stimulation of anatomically mapped neuromuscular points, founded by Sh. Lajpatrai Mehra and grounded
in the principles of Nadi Vigyan, Ayurveda, and modern physiology (Jyoti et al., 2021; Mehra, n.d.). The system
is conceptualised as acting through peripheral mechanoreceptor activation, spinal reflex modulation, autonomic
regulation, and neuroendocrine stimulation—mechanisms consistent with those reported in massage therapy,
acupressure, physiotherapy, and vagal stimulation research (Bialosky et al., 2009; Field et al., 2010; Mehta et
al., 2017). Despite anecdotal reports of clinical effectiveness across a range of neurological and psychiatric
conditions, Indian Neurotherapy remains entirely undocumented in indexed peer-reviewed clinical literature.
Recent integrative medicine literature has increasingly explored the role of non-invasive neurophysiological
interventions in chronic and systemic health conditions. Neurotherapy-based approaches have been reported to
improve physiological regulation, autonomic balance, circulation, endocrine functioning, and symptom
management across multiple clinical presentations. Dev and Dutta (2022) demonstrated a novel neurotherapy-
based approach for polycystic ovarian syndrome (PCOS), reporting improvements in hormonal and reproductive
outcomes—suggesting neurotherapy’s capacity to influence the hypothalamic–pituitary–gonadal axis. Dutta and
Dev (2024) demonstrated significant improvement in subclinical hypothyroidism following structured
neurotherapy intervention, including reduction in serum TSH without reported adverse effects. In a separate
report, Dutta and Dev (2025) documented improvements in haemoglobin levels, fatigue, and functional
wellbeing in a patient with beta-thalassemia intermedia following three-month neurotherapy intervention,
suggesting broader systemic regulatory potential.
In the pain management domain, Parihar and Gandhi (2023) evaluated neurotherapy in 92 patients with low back
pain using the Visual Analogue Scale (VAS), finding a highly significant reduction in pain scores (t = 45.307, p
< .01) following a 30-minute daily neurotherapy protocol over three months. Integrative approaches combining
neurotherapy with yoga have further demonstrated superior outcomes: Parihar and Kashyap (2024) conducted a
randomised controlled trial involving 120 participants across four groups, finding that combined yoga–
neurotherapy interventions produced superior improvements in pain reduction, disability scores, and functional
outcomes in chronic low back pain compared with either modality alone, findings corroborated in a controlled
clinical investigation presented at the International Conference on Yoga as Art and Science of Living (Parihar,
2025). The theoretical framework of LMNT Neurotherapy, as foundationally described by Jyoti et al. (2021) and
Mehra (n.d.), proposes that targeted pressure stimulation influences circulation, autonomic regulation, glandular
functioning, and physiological homeostasis through neuromuscular and neurovascular pathways. These
emerging cross-domain findings support further investigation of Indian Neurotherapy as a complementary non-
pharmacological intervention in mental health conditions, including OCD.
This CARE-compliant case report aims to address this critical gap by systematically evaluating and reporting
the clinical outcomes of structured Indian Neurotherapy in a 43-year-old female with severe, treatment-refractory
OCD of 25 years duration, using the validated OCI-R as the primary outcome measure, with follow-up data to
10 months post-primary intervention.
Page 1555
www.rsisinternational.org
INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,
MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)
ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue V, May 2026
Box 1. What is Indian Neurotherapy?
Indian Neurotherapy is a non-invasive, non-pharmacological therapeutic system rooted in Indian naturopathic
tradition, formalised and standardised by the Lajpat Rai Mehra Neurotherapy Research & Training Institute
(LMNTRTI). Founded by Sh. Lajpatrai Mehra and grounded in the ancient knowledge of ‘Nadi Vigyan’
(knowledge of the nervous system), Ayurveda, and the principles of anatomy and physiology, it is a drugless
holistic system that employs precisely calibrated external manual pressure applied to anatomically mapped
neuromuscular stimulation points corresponding to organ systems, endocrine glands, spinal nerve segments, and
autonomic ganglia (Jyoti et al., 2021; Mehra, n.d.).
Treatments are individualised based on the patient’s clinical profile and administered by trained LMNTRTI-
certified therapists. The therapeutic framework integrates contemporary neurophysiological principles—
including peripheral mechanoreceptor activation, spinal reflex modulation, autonomic regulation, and
neuroendocrine stimulation—with a holistic patient-centred philosophy. No medications, injections, or invasive
procedures are used. Dietary modifications and lifestyle guidance accompany the hands-on treatment protocol
Case Presentation
The participant was a 43-year-old married female homemaker from Haridwar, Uttarakhand, presenting
voluntarily to LMNTRTI with a 25-year history of Obsessive–Compulsive Disorder. Her OCD was characterised
by a pervasive, multi-domain symptom profile spanning all six OCI-R subscales: compulsive checking (doors,
windows, gas taps, light switches), contamination-related handwashing, contamination fear, rigid ordering and
arranging, intrusive and distressing thoughts, compulsive counting, and reluctance to discard objects. These
behaviours had progressively dominated daily functioning, severely impairing domestic activities, social
relationships, and quality of life across the preceding two and a half decades.
Significant psychiatric and medical comorbidities were documented at intake, including anxiety disorder,
recurrent suicidal ideation, diabetes mellitus (10 years), hypertension (10 years), thyroid dysfunction (14 years),
cholelithiasis, cervical pain, generalised weakness, and white vaginal discharge (Table 1). Body weight was 85
kg; sleep quality was average and non-restorative; appetite was poor. An obstructive sleep apnea (OSA)
diagnosis was incidentally established during the treatment period (11 August 2025) following an acute nocturnal
respiratory event. Prior treatments—allopathic, Ayurvedic, and homoeopathic—had failed to produce sustained
OCD symptom relief over 25 years. The participant was referred to LMNTRTI by a prior patient of the centre.
Table 1. Participant Clinical Profile
CHARACTERISTIC
DETAILS
Age / Sex
43 years / Female
Marital Status / Occupation
Married / Homemaker
Primary Diagnosis
Obsessive–Compulsive Disorder (OCD) — 25-year duration
Psychiatric Comorbidities
Generalised anxiety, suicidal ideation
Medical Comorbidities
Diabetes mellitus (10 yrs), hypertension (10 yrs), thyroid
dysfunction (14 yrs), cholelithiasis, cervical pain, white
vaginal discharge, generalised weakness
Page 1556
www.rsisinternational.org
INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,
MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)
ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue V, May 2026
Obstructive Sleep Apnea
Diagnosed 11 August 2025 (AIIMS Rishikesh; incidental
during treatment)
Weight / BMI Indicator
85 kg (overweight)
Sleep / Appetite
Average (non-restorative) / Poor
Prior Treatments Tried
Allopathic ✔ Ayurvedic ✔ Homoeopathic ✔ (no sustained
relief)
Dietary Restrictions
(LMNTRTI)
No sour foods, no non-vegetarian food, no alcohol
Baseline OCI-R Score
69/72 — Severe (maximum possible distress across 5 of 6
subscales)
Consent / Ethics
Written informed consent obtained; LMNTRTI / ICMR /
GDPR compliant
Note. OCI-R = Obsessive–Compulsive Inventory-Revised. OSA = Obstructive Sleep Apnea.
METHODOLOGY
Study Design and CARE Compliance
An observational single-case study was conducted at LMNTRTI, Uttarakhand, India. The report was prepared
in accordance with the Consensus-based Clinical Case Reporting (CARE) guidelines (Gagnier et al., 2013),
including a patient timeline (Table 2), systematic outcome assessment, and patient perspective documentation.
Written informed consent was obtained, and all data were anonymised in compliance with LMNTRTI
institutional ethical guidelines, ICMR ethical standards for observational research, and GDPR principles.
Outcome Measure: OCI-R
OCD symptom severity was assessed using the Obsessive–Compulsive Inventory-Revised (OCI-R), a validated
18-item self-report scale (Foa et al., 2002). The OCI-R measures distress across six OCD symptom domains—
Washing, Obsessing, Hoarding, Ordering, Checking, and Neutralising—each comprising three items rated on a
five-point Likert scale (0 = Not at all to 4 = Extremely; range 0–72).
A total score of ≥21 is the established clinical threshold indicating the presence of OCD (Foa et al., 2002). The
OCI-R was administered at baseline (14 June 2025), after six sessions (20 June 2025), and at post-intervention
(22 August 2025). Treatment response was defined as score reduction below the clinical threshold of 21;
complete remission as a score of 0.
Treatment Protocol
The participant received structured Indian Neurotherapy sessions administered by a certified LMNTRTI
therapist (Table 4). Sessions were conducted on consecutive weekdays during the initial phase (June 2025),
followed by an extended maintenance schedule through August 2025 and into early 2026. Dietary restrictions
were prescribed: avoidance of sour foods, non-vegetarian food, and alcohol.
Page 1557
www.rsisinternational.org
INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,
MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)
ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue V, May 2026
On 11 August 2025, an acute OSA episode required emergency evaluation at AIIMS Rishikesh, resulting in
OSA diagnosis. Physicians recommended an oxygen concentrator and pharmacological management. The
participant elected to continue neurotherapy in parallel with medical treatment, and the protocol was
subsequently modified to incorporate Oxygen Therapy, respiratory-supportive stimulation (Left Medulla + Left
Gut + Left Parathoo), and enhanced cerebrovascular circulation protocols (M-Heparin).
Table 2. CARE Clinical Timeline (Symptom Onset to 10-Month Follow-up)
DATE
EVENT
CLINICAL FINDING / OUTCOME
∼2000
OCD symptom onset (~age
18)
Compulsive checking, contamination
fear, intrusive thoughts begin
2000–2025
Multiple treatment attempts
over 25 years
Allopathic, Ayurvedic, Homoeopathic
— partial or no sustained relief
14 Jun 2025
First LMNTRTI session;
baseline OCI-R
OCI-R = 69/72 (Severe); informed
consent signed
14–20 Jun 2025
Sessions 1–6 (consecutive
daily)
Progressive reduction in compulsive
frequency and anxiety noted
20 Jun 2025
Early follow-up OCI-R
assessment
OCI-R = 35/72 (Moderate) — 49.3%
reduction in 6 days
Jun–Aug 2025
Continued sessions (7
onwards)
Ongoing improvement: sleep, appetite,
anxiety, suicidal ideation resolved
11 Aug 2025
Acute sleep apnea episode
Emergency evaluation, AIIMS
Rishikesh; OSA diagnosed; oxygen
concentrator advised
12 Aug 2025
Protocol modification
Oxygen therapy and respiratory
stimulation points added to protocol
22 Aug 2025
Post-intervention OCI-R
assessment
OCI-R = 0/72 — Complete remission
across all 6 subscales
Sep–Oct 2025
Maintenance sessions
Stable remission; continued general
wellbeing improvement
Nov 2025–Feb 2026
Continued maintenance
Same protocol; no OCD symptom
recurrence
11 Mar 2026
Return visit — new
presenting goal
Patient presented for overall fitness and
weight reduction — NOT for OCD.
Page 1558
www.rsisinternational.org
INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,
MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)
ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue V, May 2026
Sustained OCD remission confirmed at
9 months post-primary intervention
28 Apr 2026
Last documented session
General wellness; no OCD symptom
recurrence at 10+ months
Note. OSA = Obstructive Sleep Apnea. AIIMS = All India Institute of Medical Sciences.
RESULTS
OCI-R Score Progression and Clinical Significance
At baseline (14 June 2025), the participant recorded an OCI-R total score of 69/72, indicating extreme OCD
symptom distress. This score is 229% above the established clinical threshold of 21 (Foa et al., 2002), consistent
with the most severe end of the OCD spectrum. Scores of 12/12 (maximum) were recorded across five of six
subscales (Washing, Obsessing, Ordering, Checking, Neutralising), with the Hoarding subscale scoring 9/12
(Table 3).
Following six consecutive Indian Neurotherapy sessions (20 June 2025), the OCI-R total score declined to
35/72—a reduction of 34 points representing 49.3% symptom improvement. This magnitude of reduction
significantly exceeds the 25–35% threshold commonly used to define SSRI treatment response in OCD clinical
trials (Skapinakis et al., 2016), achieved here within six days of intervention. The participant’s score remained
above the clinical threshold of 21 at this point, indicating continued but moderately reduced OCD
symptomatology.
At post-intervention assessment (22 August 2025), the OCI-R total score was 0/72—complete symptomatic
remission across all 18 items and all six subscales. This represents a 100% reduction from baseline and places
the participant well below the clinical OCD threshold. Table 3 presents subscale-level data; Figures 1 and 2
illustrate total score trajectory and subscale profiles respectively.
Table 3. OCI-R Subscale Scores Across Three Assessment Time Points
OCI-R SUBSCALE
(Items)
Follow-up 20
Jun 2025
Post-
Intervention 22
Aug 2025
Max
Score
Washing (5, 11, 17)
6
0
12
Obsessing (6, 12, 18)
6
0
12
Hoarding (1, 7, 13)
5
0
12
Ordering (3, 9, 15)
6
0
12
Checking (2, 8, 14)
6
0
12
Neutralising (4, 10, 16)
6
0
12
TOTAL SCORE
35
0
72
Page 1559
www.rsisinternational.org
INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,
MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)
ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue V, May 2026
% Change from Baseline
↓ 49.3%
↓ 100%
—
Severity Category
Moderate
None
(Remission)
—
Clinical Threshold Met
(OCI-R ≥21)
Yes
No
≥21
Note. OCI-R clinical threshold: total score ≥21. Maximum per subscale = 12; total maximum = 72.
Figure 1. OCI-R total score trajectory. Dashed line = clinical OCD threshold (score ≥21). Percentage reductions
shown within bars.
Figure 2. OCI-R subscale comparison across all three assessment points. All six subscales reached zero at post-
intervention.
Extended Follow-up: 9-Month Sustained Remission
Treatment card data document that the participant continued maintenance sessions through late 2025 and into
early 2026. On 11 March 2026—approximately nine months after the primary intervention phase—the
participant returned to LMNTRTI with a new presenting health goal: overall physical fitness and weight
Page 1560
www.rsisinternational.org
INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,
MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)
ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue V, May 2026
reduction. Critically, the clinical record makes no reference to any OCD symptom recurrence at this visit or in
subsequent sessions through 28 April 2026 (last documented). The participant’s decision to attend for a non-
psychiatric wellness goal nine months after achieving OCD remission provides compelling clinical evidence of
sustained remission. Figure 3 illustrates the extended outcome trajectory.
Figure 3. Extended OCI-R score trajectory including 9-month follow-up (11 March 2026). Score of 0 maintained
at 9 months; patient presented for general wellness goals (weight management), not OCD. Coloured bands
indicate OCD severity zones.
Clinical Observations
Progress notes across the treatment period documented progressive functional recovery. From the sixth session
onward, the therapist recorded reductions in compulsive checking and cleaning frequency, decreased
contamination anxiety, improved tolerance of ambiguity, resolution of suicidal ideation, and enhanced sleep
quality. Appetite improved from poor to adequate. These observations align with the quantitative OCI-R
trajectory and support convergent validity of the outcome data. The OSA episode and subsequent recovery,
managed concurrently within the neurotherapy framework, demonstrated the adaptive capacity of the treatment
protocol in the context of an acute medical complication.
Patient Perspective
The participant had endured severe OCD for 25 years, having exhausted conventional allopathic, Ayurvedic,
and homoeopathic treatment options without achieving durable relief. The psychological and functional burden
of the disorder had permeated every domain of her daily life across more than two decades.
After the sixth Indian Neurotherapy session, the participant spontaneously expressed: “Thank you. I feel I have
reborn.” This statement, documented in the clinical record, reflects a profound subjective shift in psychological
state—a sense of restoration and relief that had been absent throughout 25 years of illness and treatment.
The most clinically meaningful expression of patient perspective, however, can be behavioural rather than
verbal: the participant’s voluntary return to LMNTRTI nine months after achieving OCD remission, this time to
address weight management and general fitness. This shift in health goals—from urgent psychiatric distress to
proactive wellness—embodies the transformation that effective OCD treatment aims to achieve, and implicitly
confirms the participant’s subjective experience of sustained recovery.
Page 1561
www.rsisinternational.org
INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,
MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)
ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue V, May 2026
DISCUSSION
This CARE-compliant case report presents, to our knowledge, the first systematically documented and OCI-R-
evaluated account of Indian Neurotherapy for Obsessive–Compulsive Disorder. The findings are clinically
remarkable: complete and sustained remission—OCI-R from 69/72 to 0/72—in a participant with severe,
treatment-refractory, 25-year-duration OCD, maintained at 9-month follow-up without pharmacological or
invasive intervention.
Contextualisation Against Standard Treatment Benchmarks
To contextualise the magnitude of improvement, it is instructive to compare outcomes against established
benchmarks for standard OCD treatments. First-line SSRI pharmacotherapy achieves treatment response (≥25–
35% symptom reduction) in 40–60% of patients, with complete remission in approximately 20–25% (Skapinakis
et al., 2016; Skoog & Skoog, 1999). Combined CBT with ERP achieves response in 60–70%, with remission
rates higher but still rarely reaching 100% (Hirschtritt et al., 2017; Simpson et al., 2013). In this case, Indian
Neurotherapy achieved 49.3% symptom reduction within six sessions—surpassing SSRI response benchmarks
in less than one week—and 100% remission by 10 weeks, sustained at 9-month follow-up. While single-case
data cannot be used to draw comparative efficacy conclusions, the magnitude and durability of observed
outcomes warrant serious clinical attention.
Proposed Neurophysiological Mechanisms
The observed reduction in OCI-R scores can reflect neurophysiological modulation associated with autonomic
balance and stress-response regulation—consistent with the broader systemic regulatory effects of Indian
Neurotherapy previously documented in endocrine and haematological case studies (Dev & Dutta, 2022; Dutta
& Dev, 2024; Dutta & Dev, 2025). These prior reports suggest that Indian Neurotherapy can exert systemic
physiological effects beyond the primary presenting condition, supporting its relevance as a multi-domain
integrative intervention. The mechanisms underlying such effects, and their applicability to psychiatric
conditions such as OCD, are explored below.
The neurophysiological basis for these outcomes can be conceptualised within a multi-pathway autonomic and
neurochemical regulatory framework. Manual pressure-based stimulation in Indian Neurotherapy activates
cutaneous and fascial mechanoreceptors, engaging Aβ and C-fibre peripheral sensory pathways and spinal reflex
arcs with downstream modulation of the autonomic nervous system—analogous to mechanisms described in
massage therapy, acupressure, physiotherapy, and osteopathic manipulation (Bialosky et al., 2009; Field et al.,
2010; Mehta et al., 2017).
The protocol’s medullary stimulation points (Points 1, 10, 11) specifically target serotonin release, acetylcholine
neurotransmission, and hypothalamic homeostasis. Given that serotonergic dysregulation is the primary
neurobiological correlate of OCD (Stein et al., 2019), targeted medullary stimulation represents a
neurophysiologically plausible mechanism for OCD symptom reduction. The adrenal cortex stimulation point
(Point 8) addresses cortisol dysregulation—a known correlate of chronic stress and anxiety—through HPA axis
modulation (Hellhammer et al., 2009). Additionally, the OCD–heart rate variability (HRV) literature documents
autonomic dysregulation as a measurable neurophysiological marker in OCD (Pittig et al., 2013); interventions
that restore vagal tone and HRV are thus mechanistically relevant.
Vagal nerve engagement—plausibly arising from cervical, medullary, and respiratory stimulation in this
protocol—activates the parasympathetic nervous system and suppresses sympathetic overactivity. Porges’
(2007) polyvagal theory establishes the vagus nerve as a fundamental regulator of emotional safety, social
engagement, and stress resilience, while Thayer and Lane (2009) link vagal tone to inhibitory control—directly
relevant to the compulsive symptom domain of OCD. George et al. (2005) demonstrated that vagal nerve
stimulation produces durable psychiatric improvements including in treatment-resistant conditions, lending
mechanistic credibility to vagally mediated effects of Indian Neurotherapy.
Page 1562
www.rsisinternational.org
INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,
MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)
ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue V, May 2026
Notably, the gastrointestinal stimulation points (Points 5–7) in this protocol—targeting hepatic, mucosal, and
intestinal function—can engage the gut–brain axis, an increasingly recognised pathway in psychiatric
neuroscience (Cryan et al., 2019). The bidirectional microbiota-gut-brain axis modulates serotonin production
(approximately 90% of the body’s serotonin is produced in the gut), stress responses, and emotional regulation,
suggesting that visceral stimulation can contribute to central neurochemical normalisation. Furthermore,
Davidson and McEwen (2012) established that mind-body interventions promote neuroplasticity and stress
regulation through sustained neuromodulatory effects, providing a framework for understanding why long-term
neurotherapy might yield durable rather than transient benefits.
Limitations and Future Directions
The present findings should be interpreted cautiously due to the single-case observational design. Several
limitations must be acknowledged.
First, as a single-case observational study, the design cannot establish causality, support statistical generalisation,
or rule out confounding factors including spontaneous symptom fluctuation, non-specific therapeutic effects
(e.g., therapeutic alliance, attention), or the natural history of a disorder with a waxing-and-waning course. The
absence of control conditions, randomisation, and blinding is an inherent constraint of this design.
Second, the concurrent diagnosis and treatment of obstructive sleep apnea—including prescription of an oxygen
concentrator and pharmacological management from 11 August 2025 onward—represents a significant
confounding variable that cannot be disentangled from the neurotherapy effect. Improved sleep quality,
reduction of nocturnal hypoxia, and enhanced cerebral oxygenation following OSA treatment can have
independently contributed to the observed OCD symptom reduction in the final weeks of intervention. Future
studies should control for or systematically document concurrent medical treatments throughout the observation
period.
Third, the OCI-R is a self-report measure administered in the clinical context of the treating institution.
Responses can have been influenced by social desirability, therapeutic rapport, or demand characteristics.
Independent, blinded administration of OCI-R and supplementary use of clinician-administered measures such
as the Yale–Brown Obsessive Compulsive Scale (Y-BOCS) are recommended in future research to mitigate this
risk.
Fourth, the post-intervention OCI-R score of 0/72—absolute zero distress across all 18 items—is an unusually
extreme outcome that warrants cautious interpretation. This score reflects patient self-report at a single post-
intervention time point and can not represent the participant’s typical day-to-day symptom burden. Floor effects
in self-report instruments and the motivational context of the assessment cannot be excluded. Independent
clinician-rated confirmation is recommended.
Fifth, the participant’s concurrent allopathic medications for diabetes, hypertension, and thyroid dysfunction
were not systematically documented or controlled for throughout the intervention period. Certain
pharmacological agents—including beta-blockers (prescribed for hypertension) and thyroid hormone
replacement—are known to influence anxiety and autonomic tone, and their potential contribution to the
observed psychiatric outcomes cannot be excluded. Comprehensive medication documentation is essential in
future neurotherapy trials.
Finally, neurophysiological outcome measures such as heart-rate variability, salivary cortisol, or neuroimaging
were not employed, precluding direct mechanistic validation. Long-term durability beyond 10 months, and the
generalisability of outcomes to other patients or OCD subtypes, cannot be inferred from a single case. Controlled
trials with rigorous methodology, larger and more diverse samples, standardised protocols, and extended follow-
up are strongly recommended.
Future research should employ randomised controlled trial designs with adequate sample sizes, active or sham
control conditions, standardised and manualized Indian Neurotherapy protocols, multi-modal outcome
assessment (OCI-R, Y-BOCS, HRV, cortisol), and follow-up periods of at least 12 months. Neuroimaging
Page 1563
www.rsisinternational.org
INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,
MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)
ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue V, May 2026
studies examining pre- and post-treatment CSTC circuit activity could directly test proposed neurophysiological
mechanisms. Multisite trials across diverse cultural and clinical populations are needed to assess generalisability.
CONCLUSION
This CARE-compliant observational case report documents complete and sustained remission of severe, 25-
year-duration, treatment-refractory Obsessive–Compulsive Disorder following structured Indian Neurotherapy
at LMNTRTI. OCI-R total scores declined from 69/72 (severe) at baseline to 0/72 (complete remission) over ten
weeks, with 49.3% improvement observed within six sessions—a response magnitude exceeding standard SSRI
benchmarks. Remission was sustained at 9-month follow-up, with the participant returning to care for general
wellness goals rather than psychiatric symptoms.
The proposed neurophysiological mechanisms—mechanoreceptor-driven autonomic rebalancing, vagal tone
modulation, serotonergic and adrenal stimulation, hypothalamic homeostasis support, and gut–brain axis
engagement—are grounded in established neurophysiological principles and provide a scientifically plausible
framework for the observed outcomes. Indian Neurotherapy represents a non-invasive, non-pharmacological,
culturally accessible, and low-cost therapeutic modality with significant potential for integrative psychiatric care
delivery. These preliminary but compelling findings demand urgent attention from clinical researchers:
controlled trials with rigorous methodology are strongly warranted to validate therapeutic efficacy and establish
evidence-based protocols for wider clinical implementation.
Table 4. Indian Neurotherapy Treatment Protocol: Stimulation Points and Physiological Rationale
#
TREATMENT
POINT
TARGET SYSTEM
PHYSIOLOGICAL
RATIONALE
1
Medulla (8)
Central Nervous System
Stimulate serotonin release by
the brain
2
IF (20) + MNS (6)
Abdominal Pain Pathways
Visceral pain relief in
abdominal region
3
Pancreas (10)
Endocrine — Pancreas
Insulin production stimulation
via β-cells
4
Gall Bladder (3)
Hepatobiliary System
Bile secretion regulation
5
Liver (12)
Hepatic Function
Ursodeoxycholic acid support
(water-soluble acids)
6
Mucus Membrane (7)
Gastrointestinal Mucosa
GI mucosal membrane
integrity
7
Large Intestine (6 Gas
I)
GI Absorption
Nutrient absorption and final
digestion
8
Adrenal (6 Ads)
Adrenal Cortex
Cortisol regulation; electrolyte
balance; anti-inflammation;
stress management
Page 1564
www.rsisinternational.org
INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,
MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)
ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue V, May 2026
9
Thyroid (4)
Endocrine — Thyroid
Hormonal balance and
metabolic regulation
10
Medulla (15)
Neurotransmission
Acetylcholine stimulation for
brain–body signal
transmission
11
Medulla (6)
Hypothalamic Regulation
Maintain homeostasis via
hypothalamus
12
Oxygen Therapy
(added post-OSA)
Cellular Oxygenation
Increase oxygen level in all
body cells
13
Lt. Med + Lt. Gut +
Lt. Parathoo
Pulmonary / Respiratory
Improve lung oxygen-
absorbing capacity
14
Heparin Treatment
Haematological
Improve systemic blood
circulation
15
M-Heparin
Cerebrovascular
Enhance cerebral blood
circulation
Note. Lt = Left; GI = Gastrointestinal. Points 12–13 added following OSA diagnosis on 11 August 2025.
Ethical Statement
Written informed consent was obtained from the participant prior to commencement of this study, in accordance
with LMNTRTI institutional ethical guidelines, ICMR ethical standards for clinical and observational research
(ICMR, 2017), and General Data Protection Regulation (GDPR) principles. No invasive procedures were
employed at any stage. All patient identifiers were anonymised prior to reporting. No personal identifiers are
disclosed in this publication. The study was conducted in accordance with the Declaration of Helsinki principles.
Conflict of Interest: The author declares no conflict of interest.
Funding: No external funding was received for this study.
Data Availability: De-identified treatment records and OCI-R scoring sheets are available on reasonable request
to the corresponding author.
REFERENCES
1. Abramowitz, J. S., Taylor, S., & McKay, D. (2009). Obsessive-compulsive disorder. The Lancet,
374(9688), 491–499.
https://doi.org/10.1016/S0140-6736(09)60240-3
2. American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed.,
text rev.).
https://doi.org/10.1176/appi.books.9780890425787
3. Bialosky, J. E., Bishop, M. D., Price, D. D., Robinson, M. E., & George, S. Z. (2009). The mechanisms
of manual therapy in the treatment of musculoskeletal pain: A comprehensive model. Manual Therapy,
14(5), 531–538.
https://doi.org/10.1016/j.math.2008.09.001
4. Cryan, J. F., O’Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M.,
Sherwin, E., Moloney, G. M., & Dinan, T. G. (2019). The microbiota-gut-brain axis. Physiological
Reviews, 99(4), 1877–2013. https://doi.org/10.1152/physrev.00018.2018
Page 1565
www.rsisinternational.org
INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,
MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)
ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue V, May 2026
5. Davidson, R. J., & McEwen, B. S. (2012). Social influences on neuroplasticity: Stress and interventions
to promote well-being. Nature Neuroscience, 15(5), 689–695. https://doi.org/10.1038/nn.3093
6. Dev, D., & Dutta, P. (2022). A novel approach to treat polycystic ovarian syndrome (PCOS) patients.
Biomedicine, 42(4), 841–843.
https://doi.org/10.51248/.v42i4.1503
7. Dutta, P., & Dev, D. (2024). Effect of neurotherapy on subclinical hypothyroidism: A case report.
Integrative Medicine Case Reports, 5(1), 14–17.
https://doi.org/10.38205/imcr.05014
8. Dutta, P., & Dev, D. (2025). Neurotherapy as a complementary approach for beta-thalassemia intermedia.
Nigerian Medical Journal: Journal of the Nigeria Medical Association, 66(2), 818–825.
https://doi.org/10.71480/nmj.v66i2.760
9. Field, T., Diego, M., & Hernandez-Reif, M. (2010). Moderate pressure is essential for massage therapy
effects. International Journal of Neuroscience, 120(5), 381–385.
https://doi.org/10.3109/00207450903579475
10. Foa, E. B., Huppert, J. D., Leiberg, S., Langner, R., Kichic, R., Hajcak, G., & Salkovskis, P. M. (2002).
The Obsessive-Compulsive Inventory: Development and validation of a short version. Psychological
Assessment, 14(4), 485–496.
https://doi.org/10.1037/1040-3590.14.4.485
11. Gagnier, J. J., Kienle, G., Altman, D. G., Moher, D., Sox, H., & Riley, D. (2013). The CARE guidelines:
Consensus-based clinical case reporting guideline development. Journal of Medical Case Reports, 7(1),
Article 223.
https://doi.org/10.1186/1752-1947-7-223
12. George, M. S., Rush, A. J., Marangell, L. B., Sackeim, H. A., Brannan, S. K., Davis, S. M., Howland,
R., & Goodnick, P. (2005). A one-year comparison of vagus nerve stimulation with treatment as usual
for treatment-resistant depression. Biological Psychiatry, 58(5), 364–373.
https://doi.org/10.1016/j.biopsych.2005.07.028
13. Goodman, W. K., Storch, E. A., & Sheth, S. A. (2021). Harmonizing the neuroscience and treatment of
obsessive-compulsive disorder. JAMA Psychiatry, 78(12), 1321–1322.
https://doi.org/10.1001/jamapsychiatry.2021.2870
14. Hellhammer, D. H., Wüst, S., & Kudielka, B. M. (2009). Salivary cortisol as a biomarker in stress
research. Psychoneuroendocrinology, 34(2), 163–171.
https://doi.org/10.1016/j.psyneuen.2008.10.026
15. Hirschtritt, M. E., Bloch, M. H., & Mathews, C. A. (2017). Obsessive-compulsive disorder: Advances in
diagnosis and treatment. JAMA, 317(13), 1358–1367.
https://doi.org/10.1001/jama.2017.2200
16. Jyoti, S., Parihar, R. G., & Gandhi, A. (2021). Neurotherapy intervention: A novel approach of healing.
Integrative Medicine Case Reports, 2(1), 28.
https://doi.org/10.38205/imcr.020128
17. Mehra, L. (n.d.). Dr. Lajpatrai Mehra's neurotherapy: A novel approach to diseases and their cure. LMNT
Publications.
18. Mehta, P., Dhapte, V., Kadam, S., & Dhapte, V. (2017). Contemporary acupressure therapy: Adroit cure
for painless recovery of therapeutic ailments. Journal of Traditional and Complementary Medicine, 7(2),
251–263.
https://doi.org/10.1016/j.jtcme.2016.06.004
19. Mukherjee, P. K., Harwansh, R. K., Bahadur, S., Banerjee, S., Kar, A., Chanda, J., Biswas, S., Ahmmed,
S. K. M., & Katiyar, C. K. (2017). Development of Ayurveda—Tradition to trend. Journal of
Ethnopharmacology, 197, 10–24. https://doi.org/10.1016/j.jep.2016.07.030
20. Parihar, R. G. (2025). Synergistic effects of yoga and Indian neurotherapy on lower back pain reduction:
A clinical investigation. In Yoga as Art and Science of Living Conference Souvenir. International
Conference on Yoga as Art and Science of Living.
21. Parihar, R. G., & Gandhi, A. (2023). Impact of neurotherapy treatment in pain relief among patients
having low back pain. International Journal of Indian Psychology, 11(3), 2060–2067.
https://doi.org/10.25215/1103.191
22. Parihar, R. G., & Kashyap, A. (2024). Integrating tradition and science: A holistic approach to lower
back pain management with yoga and neurotherapy. Research Review International Journal of
Multidisciplinary, 9(6), 87–100.
https://doi.org/10.31305/rrijm.2024.v09.n06.013
23. Pittig, A., Arch, J. J., Lam, C. W. R., & Craske, M. G. (2013). Heart rate and heart rate variability in
panic, social anxiety, obsessive-compulsive, and generalized anxiety disorders at baseline and in
response to relaxation and hyperventilation. International Journal of Psychophysiology, 87(1), 19–27.
https://doi.org/10.1016/j.ijpsycho.2012.10.012
24. Porges, S. W. (2007). The polyvagal perspective. Biological Psychology, 74(2), 116–143.
https://doi.org/10.1016/j.biopsycho.2006.06.009
Page 1566
www.rsisinternational.org
INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,
MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)
ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue V, May 2026
25. Ruscio, A. M., Stein, D. J., Chiu, W. T., & Kessler, R. C. (2010). The epidemiology of obsessive-
compulsive disorder in the National Comorbidity Survey Replication. Molecular Psychiatry, 15(1), 53–
63.
https://doi.org/10.1038/mp.2008.94
26. Sarris, J., Camfield, D., & Berk, M. (2012). Complementary medicine, self-help, and lifestyle
interventions for obsessive compulsive disorder (OCD) and the OCD spectrum: A systematic review.
Journal of Affective Disorders, 138(3), 213–221.
https://doi.org/10.1016/j.jad.2011.04.051
27. Sateia, M. J. (2014). International classification of sleep disorders—third edition: Highlights and
modifications. Chest, 146(5), 1387–1394.
https://doi.org/10.1378/chest.14-0970
28. Sharma, E., Sharma, L. P., Balachander, S., Lin, B., Bhavsar, V., Bhavsar, V., de Mamani, A., Bhugra,
D., & Reddy, Y. C. J. (2021). Comorbidities in obsessive-compulsive disorder across the lifespan: A
systematic review and meta-analysis. Frontiers in Psychiatry, 12, Article 703701.
https://doi.org/10.3389/fpsyt.2021.703701
29. Simpson, H. B., Foa, E. B., Liebowitz, M. R., Huppert, J. D., Cahill, S., Maher, M. J., McLean, C. P.,
Bender, J., Marcus, S. M., & Campeas, R. (2013). Cognitive-behavioral therapy vs risperidone for
augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder. JAMA Psychiatry, 70(11),
1190–1199.
https://doi.org/10.1001/jamapsychiatry.2013.1932
30. Skoog, G., & Skoog, I. (1999). A 40-year follow-up of patients with obsessive-compulsive disorder.
Archives of General Psychiatry, 56(2), 121–127.
https://doi.org/10.1001/archpsyc.56.2.121
31. Skapinakis, P., Caldwell, D. M., Hollingworth, W., Bryden, P., Fineberg, N. A., Salkovskis, P., Welton,
N. J., Baxter, H., Kessler, D., Churchill, R., & Lewis, G. (2016).
32. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder
in adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 3(8), 730–739.
https://doi.org/10.1016/S2215-0366(16)30069-4
33. Stein, D. J., Costa, D. L. C., Lochner, C., Miguel, E. C., Reddy, Y. C. J., Shavitt, R. G., van den Heuvel,
O. A., & Simpson, H. B. (2019). Obsessive-compulsive disorder. Nature Reviews Disease Primers, 5(1),
Article 52. https://doi.org/10.1038/s41572-019-0102-3
34. Thayer, J. F., & Lane, R. D. (2009). Claude Bernard and the heart-brain connection: Further elaboration
of a model of neurovisceral integration. Neuroscience & Biobehavioral Reviews, 33(2), 81–88.
https://doi.org/10.1016/j.neubiorev.2008.08.004
35. World Health Organization. (2022). World mental health report: Transforming mental health for all.
https://www.who.int/publications/i/item/9789240049338